Topics:
Thoracic Malignancies • Medical Oncology
How would you treat Stage III unresectable adenocarcinoma of the lung with a BRAF-V600E mutation?
Is there any role for targeted therapy, or would you consider consolidation durvalumab for these patients?
Answer from: Medical Oncologist at Academic Institution
At this time, I do not think there is any role for BRAF directed therapy in patients with stage III unresectable adenocarcinoma. The standard of care remains chemoradiation followed by durvalumab. There is no evidence to support doing anything else. Unlike EGFR, for instance, where the use of consol...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
At this time, I will still incorporate PACIFIC regimen in the treatment plan.